Radiation doses to children during modified barium swallow studies
Radiation doses to children during modified barium swallow studies
复制标题
DOI：
10.1007/s00247-006-0397-6
复制
发表时间：
2007-03-01
影响因子：
2.3
通讯作者：
Chang, Anne B.
中科院分区：
文献类型：
--
作者：
Weir, Kelly A.;McMahon, Sandra M.;Chang, Anne B.
背景：进行改良吞钡（MBS）研究的婴儿和儿童的辐射剂量数据很少。目的记录MBS儿童的筛查次数、剂量面积积（DAP）和有效剂量，并确定与筛查次数和有效剂量增加有关的因素。材料与方法前瞻性记录90例连续脉冲透视MBS研究的透视数据（筛选时间、DAP、kVp）；计算有效剂量，并分析行为、吞咽次数、吞咽功能障碍和医疗问题的影响。结果全组平均有效剂量0.0826 +/- 0.0544 mSv，筛选时间2.48 +/- 0.81 min, DAP 28.79 +/- 41.72 cGy cm(2)。三个年龄组（1.0 - 3.0岁和bb0 - 3.0岁）的有效剂量（平均分别为0.1188、0.0651和0.0529 mSv, P < 0.001）存在显著差异，但筛查时间和DAP无显著差异。有效剂量与筛查时间（P= 0.007）、DAP （P< 0.001）、吞咽次数（P= 0.007）、低龄（P= 0.017）、女性（P= 0.004）、身高（P< 0.001）相关。筛查时间与吞咽次数（P< 0.001）和DAP （P< 0.001）相关。结论接受MBS研究的儿童存在筛查时间、DAP、有效剂量以及与较高有效剂量相关的儿童和程序因素。
Background There are minimal data on radiation doses to infants and children undergoing a modified barium swallow (MBS) study.Objective To document screening times, dose area product (DAP) and effective doses to children undergoing MBS and to determine factors associated with increased screening times and effective dose.Materials and methods Fluoroscopic data ( screening time, DAP, kVp) for 90 consecutive MBS studies using pulse fluoroscopy were prospectively recorded; effective dose was calculated and data were analyzed for effects of behavior, number of swallow presentations, swallowing dysfunction and medical problems.Results Mean effective dose for the entire group was 0.0826 +/- 0.0544 mSv, screening time 2.48 +/- 0.81 min, and DAP 28.79 +/- 41.72 cGy cm(2). Significant differences were found across three age groups ( 1.0 - 3.0 and > 3.0 years) for effective dose ( mean 0.1188, 0.0651 and 0.0529 mSv, respectively; P < 0.001), but not for screening time or DAP. Effective dose was correlated with screening time ( P= 0.007), DAP ( P< 0.001), number of swallow presentations ( P= 0.007), lower age ( P= 0.017), female gender ( P= 0.004), and height ( P< 0.001). Screening time was correlated with total number of swallow presentations ( P< 0.001) and DAP ( P< 0.001).Conclusion Screening times, DAP, effective dose, and child and procedural factors associated with higher effective doses are presented for children undergoing MBS studies.